Asset profile
PF-05221304 + PF-06865571
Unknown / undisclosed
Evidence outlook · program status
Discontinued (2025-11), as a strategic decision by the sponsor
This row is the Pfizer MASH combination regimen of clesacostat (PF-05221304, ACC inhibitor) plus ervogastat (PF-06865571, DGAT-2 inhibitor), studied in the Phase 2 MIRNA trial NCT04321031. Pfizer stopped developing the combination in November 2025 and in January 2026 out-licensed ervogastat alone to Madrigal for combination with Rezdiffra; clesacostat was not part of that licence and appears nowhere on Pfizer's current pipeline page. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
30 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 30 same-indication; 13 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| PF-05221304 + PF-06865571: this drug | Phase 2 | — | Acetyl-CoA carboxylase (ACC1/ACC2) + Diacylglycerol acyltransferase 2 | ||
| Resmetirom (Rezdiffra) | Approved | Small molecule | Thyroid hormone receptor-beta | ||
| Rosuvastatin | Approved | Small molecule | HMG-CoA reductase | ||
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Approved | Peptide | GLP-1 receptor | ||
| ALN-CIDEB | Phase 3 | RNA / oligonucleotide | CIDEB | ||
| Denifanstat | Phase 3 | Small molecule | Fatty acid synthase (FASN), FASN | ||
| Efimosfermin | Phase 3 | Protein / enzyme therapeutic | FGF21 | ||
| Efimosfermin Alfa | Phase 3 | Protein / enzyme therapeutic | FGF21 receptor | ||
| Lobeglitazone (Duvie) | Phase 3 | Small molecule | PPAR-gamma | ||
| Namodenoson | Phase 3 | — | Adenosine A3 receptor | ||
| Pemvidutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| Survodutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| Belapectin | Phase 2/3 | Protein / enzyme therapeutic | Galectin-3 | ||
| GR-MD-02 | Phase 2/3 | Protein / enzyme therapeutic | Galectin-3 | ||
| ALN-HSD | Phase 2 | RNA / oligonucleotide | HSD17B13 | ||
| ALN-PNP | Phase 2 | RNA / oligonucleotide | PNPLA3 |
…and 15 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.